Renovaro Accounts Payable from 2010 to 2024

RENB Stock   0.76  0.15  24.59%   
Renovaro Biosciences' Accounts Payable is increasing over the years with slightly volatile fluctuation. Overall, Accounts Payable is expected to go to about 9.9 M this year. Accounts Payable is the amount Renovaro Biosciences owes to suppliers or vendors for products or services received but not yet paid for. It represents Renovaro Biosciences' short-term liabilities. View All Fundamentals
 
Accounts Payable  
First Reported
2011-09-30
Previous Quarter
M
Current Value
11.4 M
Quarterly Volatility
2.5 M
 
Yuan Drop
 
Covid
Check Renovaro Biosciences financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Renovaro Biosciences' main balance sheet or income statement drivers, such as Interest Expense of 1.1 M, Selling General Administrative of 25.4 M or Other Operating Expenses of 85.7 M, as well as many indicators such as Price To Sales Ratio of 1.1 K, Dividend Yield of 0.0 or PTB Ratio of 1.19. Renovaro financial statements analysis is a perfect complement when working with Renovaro Biosciences Valuation or Volatility modules.
  
Check out the analysis of Renovaro Biosciences Correlation against competitors.
For information on how to trade Renovaro Stock refer to our How to Trade Renovaro Stock guide.

Latest Renovaro Biosciences' Accounts Payable Growth Pattern

Below is the plot of the Accounts Payable of Renovaro Biosciences over the last few years. An accounting item on the balance sheet that represents Renovaro Biosciences obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of Renovaro Biosciences are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. It is the amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities. Renovaro Biosciences' Accounts Payable historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Renovaro Biosciences' overall financial position and show how it may be relating to other accounts over time.
Accounts Payable10 Years Trend
Slightly volatile
   Accounts Payable   
       Timeline  

Renovaro Accounts Payable Regression Statistics

Arithmetic Mean2,313,631
Geometric Mean1,243,537
Coefficient Of Variation138.99
Mean Deviation2,363,431
Median923,887
Standard Deviation3,215,790
Sample Variance10.3T
Range9.6M
R-Value0.67
Mean Square Error6.1T
R-Squared0.45
Significance0.01
Slope483,732
Total Sum of Squares144.8T

Renovaro Accounts Payable History

20249.9 M
20239.4 M
20225.3 M
20211.4 M
2020320.6 K
2019592.9 K
2018773.6 K

About Renovaro Biosciences Financial Statements

Renovaro Biosciences stakeholders use historical fundamental indicators, such as Renovaro Biosciences' Accounts Payable, to determine how well the company is positioned to perform in the future. Although Renovaro Biosciences investors may analyze each financial statement separately, they are all interrelated. For example, changes in Renovaro Biosciences' assets and liabilities are reflected in the revenues and expenses on Renovaro Biosciences' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Renovaro Biosciences. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Accounts Payable9.4 M9.9 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Renovaro Biosciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Renovaro Biosciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Renovaro Biosciences Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Renovaro Biosciences Stock:
Check out the analysis of Renovaro Biosciences Correlation against competitors.
For information on how to trade Renovaro Stock refer to our How to Trade Renovaro Stock guide.
You can also try the Latest Portfolios module to quick portfolio dashboard that showcases your latest portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Renovaro Biosciences. If investors know Renovaro will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Renovaro Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.98)
Return On Assets
(0.15)
Return On Equity
(0.90)
The market value of Renovaro Biosciences is measured differently than its book value, which is the value of Renovaro that is recorded on the company's balance sheet. Investors also form their own opinion of Renovaro Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Renovaro Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Renovaro Biosciences' market value can be influenced by many factors that don't directly affect Renovaro Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Renovaro Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Renovaro Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Renovaro Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.